It can be seen that single-targeted inhibition of vascular disease or inflammatory response has limitations in alleviating diabetic retinopathy, just as there are still 40% of cases of poor response to anti-VEGF antibody drugs (Mounirou et al., 2022), endophthalmitis is its common therapeutic side effect. The gene discussed is VEGFA; the disease is diabetic retinopathy.